Financial Assistance
The cost for ORGOVYX may differ based on your patients' insurance coverage. How much patients pay depends on their coverage. We can help you find out what your patients' costs may be. Call 1-833-ORGOVYX (1-833-674-6899) to learn how to request an insurance benefit review.
Help your Medicare Part D patients manage out-of-pocket (OOP) costs
Medicare Part D enrollees will not pay more than $2,400 in OOP costs for all Part D prescriptions, including ORGOVYX.1*
By the end of March, 8 out of 10 Medicare Part D standard benefit enrollees reach the OOP maximum of $2,400 and pay $0 in Part D prescription drug costs for the remainder of the calendar year whether taking ORGOVYX alone or with other medications.1,2†‡
Medicare Part D enrollees may also choose to manage monthly OOP expenses for their prescription medications by opting in to the Medicare Prescription Payment Plan and spreading their annual OOP costs into monthly installments.3§ Learn more in the flashcard below.
*The annual Medicare Part D OOP cap was established through changes enacted by the Inflation Reduction Act (IRA).
†The timeframe to reach the $2,400 OOP maximum and begin paying $0 for covered prescriptions depends on individual plan benefits and monthly medication costs.1,2
‡Source: Based on data from 2025 ($2,000 OOP maximum). ORGOVYX users from 01/2025-11/2025 were identified using the CMS Research Identifiable Files Medicare Part D claims data. This percentage represents non-low-income subsidy enrollees only.2
§Monthly payments will vary based on individual plan design and when the patient opts in to the payment plan. If the patient enrolls in the Medicare Prescription Payment Plan prior to the start of plan year, their OOP costs can be spread throughout the calendar year (January-December).3
Some eligible patients with Medicare Part D may qualify for low-income subsidy (Extra Help)‖
Patients enrolled in Medicare's Extra Help may pay lower Part D costs.
Please contact the Part D plan, or visit Medicare.gov or ssa.gov/extrahelp for more information.
‖To qualify for low-income subsidy, Medicare enrollees must have income that is less than 150% of the Federal Poverty Level, based on household size, and have resources that are within the specified limits for eligibility. Learn more at https://secure.ssa.gov/poms.nsf/lnx/0603001020.4
Commercially insured patients may pay as little as $10 for ORGOVYX
2025,90%of commercial prescription OOP costs for ORGOVYX were≤$105¶
¶Source: Symphony Health claims data from 01/2025–11/2025 (total prescriptions dispensed: n=13,402).5
Individual patient experience varies by insurance plan.
With the ORGOVYX Copay Assistance Program, eligible commercially insured patients may pay as little as $10 per month.#
For more information, call toll free
1-833-ORGOVYX (1-833-674-6899),
Monday-Friday, 8 AM-8 PM ET or visit ORGOVYXhcp.com/support.
See Terms and Conditions below.
Enroll or re-enroll in the ORGOVYX Copay Assistance Program below.
ORGOVYX Copay Assistance Program Terms, Conditions, and Eligibility Criteria
# Eligibility required. Commercially insured patients only. This copay program is subject to a calendar year maximum savings of $10,000. After the calendar year maximum savings is reached, patient will be responsible for the remaining out-of-pocket costs for ORGOVYX. The Copay Program is not valid for patients participating in Medicare, Medicaid, or other government healthcare programs. No membership fees. This offer is not health insurance. Available only to patients who have been diagnosed with an FDA-approved indication for ORGOVYX. Terms and conditions apply. For full program terms, conditions, and eligibility criteria please see full terms and conditions.
ORGOVYX is covered on TRICARE tier 2 uniform formulary with prior authorization (PA)6,7
Learn more about the ORGOVYX distribution network, where prescriptions can be filled, and support information for eligible pharmacies, specialty pharmacies, and authorized distributors. Access the TRICARE PA request forms below.**
**The formulary coverage information and prior authorization (PA) form were developed independently by TRICARE. Nothing herein may be construed as an endorsement, approval, recommendation, representation, or warranty of any kind by TRICARE. Sumitomo Pharma America, Inc. and Pfizer, Inc. did not influence the coverage determination or the development of the PA form by TRICARE.
Military (MTF)
Up to 90-day supply
Tier 2 uniform formulary coverage rules apply;
PA required
Home Delivery
Up to 90-day supply
Tier 2 uniform formulary coverage rules apply;
PA required
Note: Accredo provides specialty pharmacy services through TRICARE Pharmacy Home Delivery. Outside of TRICARE Pharmacy Home Delivery, payer-affiliated specialty pharmacies do not have access to ORGOVYX.
Retail
Up to 30-day supply
Tier 2 uniform formulary coverage rules apply
PA required
Military (MTF)
Up to 90-day supply
Tier 2 uniform formulary coverage rules apply
PA required
$0††
Home Delivery
Up to 90-day supply
Tier 2 uniform formulary coverage rules apply
PA required
$44‡‡
Note: Accredo provides specialty pharmacy services through TRICARE Pharmacy Home Delivery. Outside of TRICARE Pharmacy Home Delivery, payer-affiliated specialty pharmacies do not have access to ORGOVYX.
Retail
Up to 30-day supply
Tier 2 uniform formulary coverage rules apply
PA required
$48‡‡
††$0 copay applies at military point of service if PA is approved.
‡‡$0 copay applies to active duty at any point of service if PA is approved.
Access helpful materials for
you and your patients
IMPORTANT SAFETY
INFORMATION & INDICATIONIMPORTANT SAFETY INFORMATION
Contraindication
ORGOVYX is contraindicated in patients with severe hypersensitivity to relugolix or to any of the product components.
Warnings and Precautions
QT/QTc Interval Prolongation: Androgen deprivation therapy, such as ORGOVYX may prolong the QT/QTc interval. Providers should consider whether the benefits of androgen deprivation therapy outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, or frequent electrolyte abnormalities and in patients taking drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected. Consider periodic monitoring of electrocardiograms and electrolytes.
Hypersensitivity: Angioedema was reported in 0.2% of patients treated with ORGOVYX in HERO. Hypersensitivity reactions, including pharyngeal edema and other serious cases of angioedema, have been reported post-marketing with ORGOVYX. Advise patients who experience any symptoms of hypersensitivity to temporarily discontinue ORGOVYX and promptly seek medical care. Discontinue ORGOVYX for severe hypersensitivity reactions and manage as clinically indicated.
Embryo-Fetal Toxicity: The safety and efficacy of ORGOVYX have not been established in females. Based on findings in animals and mechanism of action, ORGOVYX can cause fetal harm and loss of pregnancy when administered to a pregnant female. Advise males with female partners of reproductive potential to use effective contraception during treatment and for 2 weeks after the last dose of ORGOVYX.
Laboratory Testing: Therapy with ORGOVYX results in suppression of the pituitary gonadal system. Results of diagnostic tests of the pituitary gonadotropic and gonadal functions conducted during and after ORGOVYX may be affected. The therapeutic effect of ORGOVYX should be monitored by measuring serum concentrations of prostate-specific antigen (PSA) periodically. If PSA increases, serum concentrations of testosterone should be measured.
Adverse Reactions
Serious adverse reactions occurred in 12% of patients receiving ORGOVYX. Serious adverse reactions in ≥0.5% of patients included myocardial infarction (0.8%), acute kidney injury (0.6%), arrhythmia (0.6%), hemorrhage (0.6%), and urinary tract infection (0.5%). Fatal adverse reactions occurred in 0.8% of patients receiving ORGOVYX including metastatic lung cancer (0.3%), myocardial infarction (0.3%), and acute kidney injury (0.2%). Fatal and non-fatal myocardial infarction and stroke were reported in 2.7% of patients receiving ORGOVYX.
Most common adverse reactions (≥10%) and laboratory abnormalities (≥15%) in patients receiving ORGOVYX were hot flush (54%), glucose increased (44%), triglycerides increased (35%), musculoskeletal pain (30%), hemoglobin decreased (28%), alanine aminotransferase increased (27%), fatigue (26%), aspartate aminotransferase increased (18%), constipation (12%), and diarrhea (12%).
Drug Interactions
Co-administration of ORGOVYX with an oral P-gp inhibitor increases relugolix exposure, which may increase the risk of adverse reactions associated with ORGOVYX. Avoid co-administration of ORGOVYX with oral P-gp inhibitors. If co-administration is unavoidable, take ORGOVYX first and separate dosing by at least 6 hours. Monitor patients for increased adverse reactions. Treatment with ORGOVYX may be interrupted for up to 2 weeks if a short course of treatment with a P-gp inhibitor is required. Resume ORGOVYX after the P-gp inhibitor is discontinued. If treatment with ORGOVYX is interrupted for greater than 7 days, restart ORGOVYX with a 360 mg loading dose on the first day and continue with 120 mg once daily.
Co-administration of ORGOVYX with a combined P-gp and strong CYP3A inducer decreases relugolix exposure, which may reduce the effects of ORGOVYX. Avoid co-administration of ORGOVYX with combined P-gp and strong CYP3A inducers. If co-administration is unavoidable, increase the ORGOVYX dose to 240 mg once daily. After discontinuation of the combined P-gp and strong CYP3A inducer, resume the recommended ORGOVYX dose of 120 mg once daily.
INDICATION
ORGOVYX® (relugolix) is a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of adult patients with advanced prostate cancer.
Please see full Prescribing Information for ORGOVYX.